# Sugammadex Dosage Based on Ideal Body Weight for Profound Rocuronium-induced Neuromuscular Blockade Reversal in Morbidly Obese Patients

> **NCT02545595** · PHASE2 · COMPLETED · sponsor: **Poitiers University Hospital**

## Conditions studied

- Morbid Obesity

## Interventions

- **DRUG:** Sugammadex 1 mg/kg
- **DRUG:** Sugammadex 2 mg/kg
- **DRUG:** Sugammadex 4 mg/kg

## Key facts

- **NCT ID:** NCT02545595
- **Lead sponsor:** Poitiers University Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-05
- **Primary completion:** 2013-12
- **Final completion:** —
- **Target enrollment:** — (—)
- **Last updated:** 2016-10-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02545595

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02545595, "Sugammadex Dosage Based on Ideal Body Weight for Profound Rocuronium-induced Neuromuscular Blockade Reversal in Morbidly Obese Patients". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02545595. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*